A Rationale for the Use of Ivabradine in the Perioperative Phase of Cardiac Surgery: A Review
Abstract
1. Introduction
2. Pathophysiological Effects of Ivabradine
2.1. Heart Rate Control
2.2. Inflammation and Oxidative Stress
2.3. Left Ventricular Diastolic Function
3. The Role of Ivabradine Treatment in Specific Perioperative Clinical States
3.1. Postoperative Low Cardiac Output Syndrome (Table 2)
Study (Year) | Type of Study | Sample Size | Design of the Study | Clinical Effect | Possible Role in a Specific Perioperative Clinical Context |
---|---|---|---|---|---|
Shah et al. (2024) [25] | Prospective clinical trial | 200 patients | Patients admitted with acute HF were randomized to receive either standard HF treatment alone or standard treatment with adjunctive ivabradine therapy | The ivabradine treatment group had a significantly greater increase in EF (p < 0.001) and HR reduction (p < 0.05) | Postoperative LCOS |
Nguyen et al. 2018 [28] | Phase 2, multicenter, single-blind, and randomized controlled trial | 19 patients | Patients with LVEF < 40% presenting sinus tachycardia following dobutamine infusion for LCOS after CABG operation received either ivabradine or placebo | Ivabradine decreased HR (p < 0.001) and increased CI (p = 0.02), SV (p < 0.001), and systolic BP (p = 0.03) | Postoperative LCOS |
Tekin et al. 2022 [29] | Single-center and retrospective study | 174 patients | Patients who underwent off-pump CABG were divided into Group I, who received ivabradine, and Group M, who received metoprolol before surgery until postoperative day 10 | The rates of hypotension and intraoperative inotropic support did not differ significantly (p = 0.47 and p = 0.87, respectively) | N/A |
3.2. Postoperative Atrial Fibrillation
4. The Role of Ivabradine in the Modulation of Neural and Psychological Responses
4.1. HCN Channels and Neurotransmission
4.2. Postoperative Stress, Anxiety, and Pain
5. Conclusions and Future Directions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
HR | heart rate |
HCN | hyperpolarization-activated cyclic nucleotide-gated |
cAMP | cyclic adenosine monophosphate |
AF | atrial fibrillation |
CABG | coronary artery bypass grafting |
eNOS | endothelial nitric oxide synthase |
mTOR | mammalian target of rapamycin |
VCAM-1 | cytokine vascular cell adhesion molecule 1 |
MCP-1 | monocyte chemotactic protein-1 |
NADP | nicotinamide adenine dinucleotide phosphate |
ROS | reactive oxygen species |
LV | left ventricle |
LVEF | left ventricular ejection fraction |
NYHA | New York Heart Association |
LCOS | low cardiac output syndrome |
POAF | postoperative atrial fibrillation |
ICU | intensive care unit |
PNS | peripheral nervous system |
CNS | central nervous system |
DRG | dorsal root ganglion |
References
- Biel, M.; Wahl-Schott, C.; Michalakis, S.; Zong, X. Hyperpolarization-activated cation channels: From genes to function. Physiol. Rev. 2009, 89, 847–885. [Google Scholar] [CrossRef] [PubMed]
- Herrmann, S.; Stieber, J.; Stöckl, G.; Hofmann, F.; Ludwig, A. Hcn4 provides a ‘depolarization reserve’ and is not required for heart rate acceleration in mice. EMBO J. 2007, 26, 4423–4432. [Google Scholar] [CrossRef]
- DiFrancesco, J.C.; DiFrancesco, D. Dysfunctional HCN ion channels in neurological diseases. Front. Cell. Neurosci. 2015, 6, 174. [Google Scholar] [CrossRef] [PubMed]
- Cao, Y.; Pang, J.; Zhou, P. Hcn channel as therapeutic targets for heart failure and pain. Curr. Top. Med. Chem. 2016, 16, 1855–1861. [Google Scholar] [CrossRef]
- Ramentol, R.; Perez, M.; Larsson, H. Gating mechanism of hyperpolarization-activated hcn pacemaker channels. Nat. Commun. 2020, 11, 1419. [Google Scholar] [CrossRef]
- Byczkowicz, N.; Eshra, A.; Montanaro, J.; Trevisiol, A.; Hirrlinger, J.; Kole, M.H.; Shigemoto, R.; Hallermann, S. HCN channel-mediated neuromodulation can control action potential velocity and fidelity in central axons. Elife 2019, 8, e42766. [Google Scholar] [CrossRef] [PubMed]
- Abdel-Salam, Z.; Nammas, W. Atrial Fibrillation After Coronary Artery Bypass Surgery: Can Ivabradine Reduce Its Occurrence? J. Cardiovasc. Electrophysiol. 2016, 27, 670–676. [Google Scholar] [CrossRef]
- Iliuta, L.; Rac-Albu, M. Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Cardiac Surgery. Cardiol. Ther. 2014, 3, 13–26. [Google Scholar] [CrossRef]
- Miyake, S.; Higuchi, H.; Honda-Wakasugi, Y.; Fujimoto, M.; Kawai, H.; Nagatsuka, H.; Maeda, S.; Miyawaki, T. Locally injected ivabradine inhibits carrageenan-induced pain and inflammatory responses via hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. PLoS ONE 2019, 14, e0217209. [Google Scholar] [CrossRef]
- Ondičová, K.; Hegedusova, N.; Tibenský, M.; Mravec, B. Ivabradine reduces baseline and stress-induced increase of heart rate and blood pressure and modulates neuroendocrine stress response in rats depending on stressor intensity. Gen. Physiol. Biophys. 2019, 38, 165–173. [Google Scholar] [CrossRef]
- Woodman, R.; Student, J.; Miller, C.; Lockette, W. Ivabradine-induced bradycardia is accompanied by reduced stress-related anxiety. Am. J. Hypertens. 2023, 36, 316–323. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, P.; Bhavsar, N.; Naik, D.; Shah, D. Comparative effectiveness of metoprolol, ivabradine, and its combination in the management of inappropriate sinus tachycardia in coronary artery bypass graft patients. Indian J. Pharmacol. 2021, 53, 264–269. [Google Scholar] [CrossRef] [PubMed]
- Boeken, U.; Albert, A.; Mehdiani, A.; Sowinski, B.; Westenfeld, R.; Aubin, H.; Saeed, D.; Akhyari, P.; Lichtenberg, A. Efficacy and Safety of Ivabradine Application in the Early Period after Heart Transplantation. J. Heart Lung Transplant. 2019, 38, S292. [Google Scholar] [CrossRef]
- Zhang, R.; Bobylev, D.; Stiefel, P.; Haverich, A.; Bara, C. Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: Results of 48-month study. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2012, 101, 631–636. [Google Scholar] [CrossRef]
- Doesch, A.O.; Mueller, S.; Erbel, C.; Gleissner, C.A.; Frankenstein, L.; Hardt, S.; Ruhparwar, A.; Ehlermann, P.; Dengler, T.; Katus, H.A. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: A long-term follow-up study. Drug Des. Dev. Ther. 2013, 7, 1323–1328. [Google Scholar] [CrossRef] [PubMed]
- Marazia, S.; Urso, L.; Contini, M.; Pano, M.; Zaccaria, S.; Lenti, V.; Sarullo, F.M.; Di Mauro, M. The Role of Ivabradine in Cardiac Rehabilitation in Patients With Recent Coronary Artery Bypass Graft. J. Cardiovasc. Pharmacol. Ther. 2015, 20, 547–553. [Google Scholar] [CrossRef]
- Virmani, S.; Mallik, I.; Mohire, V.B.; Geelani, M.A.; Minhas, H.S. Effect of preoperative ivabradine on hemodynamics during elective off-pump CABG. Ann. Card. Anaesth. 2023, 26, 260–267. [Google Scholar] [CrossRef]
- Li, B.; Zhang, J.; Wang, Z.; Chen, S. Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway. PLoS ONE 2016, 11, e0149694. [Google Scholar] [CrossRef] [PubMed]
- Luong, L.; Duckles, H.; Schenkel, T.; Mahmoud, M.; Tremoleda, J.L.; Wylezinska-Arridge, M.; Ali, M.; Bowden, N.P.; Villa-Uriol, M.C.; van der Heiden, K.; et al. Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflammatory mechanisms in arteries. Thromb. Haemost. 2016, 116, 181–190. [Google Scholar]
- Custodis, F.; Baumhäkel, M.; Schlimmer, N.; List, F.; Gensch, C.; Böhm, M.; Laufs, U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117, 2377–2387. [Google Scholar] [CrossRef]
- Kröller-Schön, S.; Schulz, E.; Wenzel, P.; Kleschyov, A.L.; Hortmann, M.; Torzewski, M.; Oelze, M.; Renné, T.; Daiber, A.; Münzel, T. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. Basic Res. Cardiol. 2011, 106, 1147–1158. [Google Scholar] [CrossRef]
- Cacciapuoti, F.; Magro, V.M.; Caturano, M.; Lama, D.; Cacciapuoti, F. The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study. J. Cardiovasc. Echogr. 2017, 27, 126–131. [Google Scholar] [CrossRef] [PubMed]
- Panayotova, D.; Slavov, M.; Krasnaliev, Y.; Panayotov, P.L. Echocardiographic evaluation of changes in diastolic dysfunction after CABG surgery, effect of novel therapy with Ivabradine. J. Cardiothorac. Surg. 2013, 8 (Suppl. S1), O295. [Google Scholar] [CrossRef]
- Khedr, E.; Elashmawy, H.; Alawady, S.; Attia, A.; Samir, S.; Helmy, E.; Mahmoud, E. Echocardiographic Assessment of Diastolic Dysfunction and the Efficacy of Ivabradine Therapy Post-CABG Surgery. J. Acute Care Resusc. 2024, 1, 80–85. [Google Scholar] [CrossRef]
- Shah, I.; Khan, M.; Sher, A.; Khan, S.; Ullah, S. Assessing the efficacy and safety of ivabradine as adjunctive therapy in acute heart failure: A prospective clinical trial. Ann. Pims-Shaheed Zulfiqar Ali Bhutto Med. Univ. 2024, 20 (Suppl. S1), 589–593. [Google Scholar] [CrossRef]
- Pereira-Barretto, A.C. Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure. Adv. Ther. 2015, 32, 906–919. [Google Scholar] [CrossRef]
- Borer, J.S.; Swedberg, K.; Komajda, M.; Ford, I.; Tavazzi, L.; Böhm, M.; Depre, C.; Wu, Y.; Maya, J.; Dominjon, F. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology 2017, 136, 138–144. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, L.S.; Squara, P.; Amour, J.; Carbognani, D.; Bouabdallah, K.; Thierry, S.; Apert-Verneuil, C.; Moyne, A.; Cholley, B. Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: A phase 2 exploratory randomized controlled trial. Crit. Care 2018, 22, 193. [Google Scholar] [CrossRef]
- Tekin, E.E.; Yeşiltaş, M.A.; Haberal, İ. Short-Term Results of Ivabradine versus Metoprolol: The Effects on Atrial Fibrillation in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting. Braz. J. Cardiovasc. Surg. 2022, 37, 857–865. [Google Scholar] [CrossRef]
- El-saied, Y.; Ahmed, A.; Mohamed, M.; Elbadawy, M. Postoperative Atrial Fibrillation Prevention in Patients Undergoing Coronary Artery Bypass Grafting by Using Perioperative HCN Channel Blockers and Selective Beta Blockers. Egypt. J. Hosp. Med. 2024, 95, 2027–2032. [Google Scholar] [CrossRef]
- Tibbs, G.R.; Posson, D.J.; Goldstein, P.A. Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? Trends Pharmacol. Sci. 2016, 37, 522–542. [Google Scholar] [CrossRef]
- Cangiano, L.; Gargini, C.; Santina, L.; Demontis, G.; Cervetto, L. High-pass filtering of input signals by the ih current in a non-spiking neuron, the retinal rod bipolar cell. PLoS ONE 2007, 2, e1327. [Google Scholar] [CrossRef]
- Ko, K.; Rasband, M.; Meseguer, V.; Krämer, R.; Golding, N. Serotonin modulates spike probability in the axon initial segment through hcn channels. Nat. Neurosci. 2016, 19, 826–834. [Google Scholar] [CrossRef]
- Hatch, R.J.; Jennings, E.A.; Ivanusic, J.J. Peripheral hyperpolarization-activated cyclic nucleotide-gated channels contribute to inflammation-induced hypersensitivity of the rat temporomandibular joint. Eur. J. Pain 2013, 17, 972–982. [Google Scholar] [CrossRef]
- Young, G.T.; Emery, E.C.; Mooney, E.R.; Tsantoulas, C.; McNaughton, P.A. Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels. Pain 2014, 155, 1708–1719. [Google Scholar] [CrossRef]
- Dini, L.; Del Lungo, M.; Resta, F.; Melchiorre, M.; Spinelli, V.; Di Cesare Mannelli, L.; Ghelardini, C.; Laurino, A.; Sartiani, L.; Coppini, R.; et al. Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain. Front. Pharmacol. 2018, 9, 1252. [Google Scholar] [CrossRef]
- Noh, S.; Kumar, N.; Bukhanova, N.; Chen, Y.; Stemkowsi, P.; Smith, P. The heart-rate-reducing agent, ivabradine, reduces mechanical allodynia in a rodent model of neuropathic pain. Eur. J. Pain 2014, 18, 1139–1147. [Google Scholar] [CrossRef]
- Tanaka, S.; Ishida, T.; Ishida, K.; Fuseya, S.; Ito, M.; Sakamoto, A.; Kawamata, M. A randomized, double-blinded, placebo-controlled, crossover study of the HCN channel blocker ivabradine in a capsaicin-induced pain model in healthy volunteers. Sci. Rep. 2022, 12, 17246. [Google Scholar] [CrossRef] [PubMed]
- Ohashi, N.; Uta, D.; Ohashi, M.; Baba, H. Analgesic effect of ivabradine against inflammatory pain mediated by hyperpolarization-activated cyclic nucleotide-gated cation channels expressed on primary afferent terminals in the spinal dorsal horn. Pain 2022, 163, 1356–1369. [Google Scholar] [CrossRef] [PubMed]
- Lee, M.C.; Bond, S.; Wheeler, D.; Scholtes, I.; Armstrong, G.; McNaughton, P.; Menon, D. A randomised, double-blind, placebo-controlled crossover trial of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model: An enriched population trial. Pain 2019, 160, 2554–2565. [Google Scholar] [CrossRef] [PubMed]
- Vakhitova, E. The effect of heart rate on quality of life in patients with chronic heart failure. Ural. Med. J. 2025, 24, 59–69. [Google Scholar] [CrossRef]
- Nakano, Y.; Ando, H.; Suzuki, W.; Ohashi, H.; Suzuki, Y.; Takashima, H.; Amano, T. Impact of ivabradine in decompensated heart failure due to cancer therapy-related cardiac dysfunction. Clin. Case Rep. 2021, 9, e04133. [Google Scholar] [CrossRef]
- Izumida, T.; Imamura, T.; Nakamura, M.; Fukuda, N.; Kinugawa, K. How to consider target heart rate in patients with systolic heart failure. ESC Heart Fail. 2020, 7, 3231–3234. [Google Scholar] [CrossRef] [PubMed]
- Swedberg, K.; Komajda, M.; Böhm, M.; Borer, J.S.; Ford, I.; Dubost-Brama, A.; Lerebours, G.; Tavazzi, L.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010, 376, 875–885. [Google Scholar] [CrossRef] [PubMed]
Study (Year) | Key Question | Possible Pathophysiological Pathway | Main Results |
---|---|---|---|
Li et al. (2016) [18] | Vascular anti-inflammatory effects | Possible impact on LSS-induced inflammation and endothelial injury and the role of eNOS | -Endothelial protection from LSS-induced inflammation and oxidative stress -Slowdown in the progress of plaque formation by altering eNOS activity (mediated by the mTOR pathway) |
Luong et al. (2016) [19] | Vascular anti-inflammatory effects | Possible vascular protection by increasing WSS to reduce vascular inflammation | -Reduction in expression of pro-inflammatory VCAM-1 -Enhancement in expression of anti-inflammatory eNOS at the inner curvature of the aorta -HR reduction and WSS enhancement in the aorta |
Custodis et al. (2008) [20] | Effects on endothelial function and atherogenesis | Possible improvement in endothelial function and reduction in oxidative stress and atherosclerotic plaque formation through selective HR reduction | Selective HR reduction: -had no effect on the number of endothelial progenitor cells -did not alter aortic eNOS activity -decreased MCP-1 mRNA -decreased markers of superoxide production and lipid peroxidation in the aortic wall -reduced NADPH oxidase activity |
Kröller-Schön et al. (2011) [21] | Effects on endothelial function | Possible influence of ivabradine on oxidative stress and endothelial dysfunction through HR reduction | -Antioxidative effects occurred through decreased NADPH oxidase activity and the prevention of eNOS uncoupling -Attenuation of angiotensin II signaling and additional vascular benefits |
Study (Year) | Type of Study | Sample Size | Design of the Study | Clinical Effect | Possible Role in a Specific Perioperative Clinical Context |
---|---|---|---|---|---|
El-saied et al. 2024 [30] | Prospective interventional study | 50 patients | Patients who underwent elective CABG surgery were divided into Group I, who received both ivabradine and bisoprolol, and Group II, who received bisoprolol only, 48 h before and one week after surgery | There was a statistically significant increase in the POAF incidence among patients in Group II (p = 0.01) | POAF |
Abdel-Salam et al. 2016 [7] | Prospective, nonrandomized, multicenter, and observational study | 740 patients | Patients scheduled for elective CABG operation were divided into three treatment groups: ivabradine and bisoprolol group, ivabradine-only group, and bisoprolol-only group (each treatment started 48 h before surgery and ended one week afterwards) | The incidence of POAF was significantly lower in the ivabradine and bisoprolol group 3 compared to the ivabradine-only group and bisoprolol-only group (p < 0.001 for both) | POAF |
Iliuta et al. 2014 [8] | Open-label randomized clinical trial | 527 patients | Patients with conduction abnormalities or LV systolic dysfunction underwent CABG or valvular surgery and were randomized into three treatment groups: the ivabradine-only group, the metoprolol-only group, and the metoprolol plus ivabradine group (each treatment started 2 days before surgery and ended ≥10 days postoperatively) | In-hospital POAF occurred less frequently with combined therapy than with metoprolol or ivabradine alone (p < 0.001) | POAF |
Study (Year) | Type of Study | Aim of the Study | Key Pathophysiological Mechanism | Main Results | Possible Role in the Context of Perioperative Management of Stress, Pain, and Anxiety |
---|---|---|---|---|---|
Noh et al. (2014) [37] | Animal study | Investigation of the effects of ivabradine on NP | Peripheral nerve injury increases the excitability of primary sensory neurons, triggering the onset of NP. Changes in HCN channels are implicated in this process | -Ivabradine significantly reduced NP (mechanical allodynia) -MAP was maintained -A HR reduction of 15% was observed | Pain management |
Tanaka et al. (2022) [38] | Randomized double-blinded, placebo-controlled, and crossover study | Evaluation of the analgesic effect of 2-day administration of ivabradine on a capsaicin pain model | Ivabradine alleviates mechanical allodynia with NP via inhibition of the HCN current in large dorsal root ganglion | -There was no significant difference in spontaneous pain or flare size between the ivabradine and placebo groups -The area of dynamic mechanical allodynia in the ivabradine group was significantly smaller | Pain management |
Ohashi eta al. (2022) [39] | Animal study | Investigation of the spinal action and cellular mechanisms underlying ivabradine’s analgesic effects against inflammatory pain | Spinal responses mediated by HCN channels on primary afferent terminals are affected by the central and peripheral administration of ivabradine | -Spinal responses mediated by HCN channels on primary afferent terminals are suppressed by the administration of ivabradine -Ivabradine preferentially acts on C-fiber terminals of spinal dorsal horn neurons, inducing a stronger inhibition of neuronal excitability in inflammatory pain | Pain management |
Miyake et al. (2019) [9] | Animal study | Evaluation of ivabradine’s effect on inflammatory pain | Ivabradine acts on peripheral sensory neurons and has inhibitory effects on neuropathic pain. It also acts on HCN channels, which are involved in the modulation of inflammatory pain | -Ivabradine affects inflammation responses, including the accumulation of leukocytes and TNF-alpha expression -Ivabradine also plays a role in neuropathic pain reduction | Pain management |
Lee et al. (2019) [40] | Single-center, randomized, double-blind, placebo-controlled, and 2-period crossover trial | Evaluation of the influence of ivabradine on capsaicin-induced hyperalgesia and pain in healthy human subjects | Possible analgesic potential of peripherally acting non-selective HCN blockers | -Ivabradine caused a HR reduction -There were no significant effects of ivabradine on the primary outcome, defined as a difference in the effects of placebo and ivabradine on the area of punctate hyperalgesia | |
Ondicova et al. (2019) [10] | Animal study | Investigation of ivabradine’s stress-induced effects on HR, BP, and neuroendocrine stress response | Possible influence of ivabradine on signaling that accompanies a stress-induced rise in HR and the extent of the neuroendocrine stress response (sympathoadrenal system and hypothalamic–pituitary–adrenocortical axis) | -Ivabradine significantly lowers values of HR and BP -It significantly reduces handling-induced epinephrine and norepinephrine release into the bloodstream | Stress reduction |
Woodman et al. (2023) [11] | Animal study | Evaluation of the effect of ivabradine treatment on anxiety reduction | A reduction in funny channel currents brought about by the targeted disruption of HCN gene expression and the inhibition of cyclic nucleotide binding to HCN channels in the brain has been shown to improve coping in animal models of stress | -Ivabradine reduces resting HR -Stressed mice treated with ivabradine displayed significantly greater exploratory behavior according to the qualitative cognition and anxiety assessment | Anxiety management and stress reduction |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ballas, C.E.; Katsouras, C.S.; Siaravas, K.C.; Tzourtzos, I.; Moula, A.I.; Alexiou, C. A Rationale for the Use of Ivabradine in the Perioperative Phase of Cardiac Surgery: A Review. J. Cardiovasc. Dev. Dis. 2025, 12, 294. https://doi.org/10.3390/jcdd12080294
Ballas CE, Katsouras CS, Siaravas KC, Tzourtzos I, Moula AI, Alexiou C. A Rationale for the Use of Ivabradine in the Perioperative Phase of Cardiac Surgery: A Review. Journal of Cardiovascular Development and Disease. 2025; 12(8):294. https://doi.org/10.3390/jcdd12080294
Chicago/Turabian StyleBallas, Christos E., Christos S. Katsouras, Konstantinos C. Siaravas, Ioannis Tzourtzos, Amalia I. Moula, and Christos Alexiou. 2025. "A Rationale for the Use of Ivabradine in the Perioperative Phase of Cardiac Surgery: A Review" Journal of Cardiovascular Development and Disease 12, no. 8: 294. https://doi.org/10.3390/jcdd12080294
APA StyleBallas, C. E., Katsouras, C. S., Siaravas, K. C., Tzourtzos, I., Moula, A. I., & Alexiou, C. (2025). A Rationale for the Use of Ivabradine in the Perioperative Phase of Cardiac Surgery: A Review. Journal of Cardiovascular Development and Disease, 12(8), 294. https://doi.org/10.3390/jcdd12080294